⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

AKUMS - Fundamental Analysis: Financial Health & Valuation

← Back to List

⭐ Rating: 3

Last Updated Time : 02 Aug 26, 04:58 pm

Key Parameters

⭐ Fundamental Rating: 3.0

Stock CodeAKUMS
Market Cap10,357 Cr.
Current Price658 ₹
High / Low715 ₹
Stock P/E88.8
Book Value154 ₹
Dividend Yield0.15 %
ROCE6.82 %
ROE4.92 %
Face Value2.00 ₹
DMA 50625 ₹
DMA 200546 ₹
Chg in FII Hold0.53 %
Chg in DII Hold-0.92 %
PAT Qtr17.1 Cr.
PAT Prev Qtr31.0 Cr.
RSI52.1
MACD15.4
Volume1,66,137
Avg Vol 1Wk1,59,836
Low price409 ₹
High price715 ₹
PEG Ratio-4.37
Debt to equity0.02
52w Index81.4 %
Qtr Profit Var-38.1 %
EPS7.09 ₹
Industry PE33.8

✅ Positive

AKUMS demonstrates strong revenue growth, albeit recently impacted by a significant quarterly decline. The company’s debt levels are exceptionally low, providing financial flexibility and suggesting prudent capital management. A negative PEG ratio indicates the stock might be undervalued relative to earnings growth expectations.

⚠️ Limitation

The substantial profit decrease in the most recent quarter raises concerns about operational headwinds or potentially unsustainable revenue growth. High P/E ratios often reflect high-growth expectations, which could prove difficult to maintain, increasing downside risk. FII holding has decreased while DII holding is declining, signalling a lack of investor confidence.

📉 Company Negative News

The ‘Hold’ rating from marketsmojo.com and the news regarding the sale of plants and warehouses (₹56 crore) suggest a strategic shift into the cosmetics market, but doesn't immediately translate to profitability. The financial news indicates recent profit volatility.

📈 Company Positive News

None found.

🏭 Industry

The pharmaceutical sector is characterized by stringent regulatory requirements, intense competition, and fluctuating drug prices. However, companies specializing in contract research and manufacturing services (CRAMS), like AKUMS, can enjoy relatively stable revenue streams driven by demand for generic drugs and custom formulations. This particular segment is evolving towards higher value-added services.

🧾 Conclusion

Considering the current valuation metrics and recent profit drop, a potential entry zone could be around 600 ₹ – 620 ₹, representing a slight discount to the current price. For long-term holding guidance, investors should closely monitor AKUMS's progress in its newly entered cosmetics market, as well as any adjustments to its CRAMS business. The stock is currently trading with reasonable leverage but requires careful observation for sustainable growth and improved profitability.

Technical Analysis
Fundamental Analysis

NIFTY 50 · Fundamental

NEXT 50 · Fundamental

MIDCAP · Fundamental

SMALLCAP · Fundamental